PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announces that its products are the subject of 10 poster presentations and abstracts to be featured at the Spring Symposium on Advanced Wound Care (SAWC). Derma Sciences also announces a new corporate branding campaign focused on driving awareness of the company’s leadership in tissue regeneration and wound healing. This campaign features a new corporate logo and the “A Tissue Regeneration Company” tagline, and will debut at the SAWC and at the 2014 MedAssets Healthcare Business Summit, two important conferences being held this week for clinicians dedicated to wound healing.
Derma Sciences will showcase its advanced wound care product line at booth number 509 at the SAWC at the Gaylord Palms Resort and Convention Center in Orlando from April 24 to April 27. The MedAssets Healthcare Business Summit is being held at the Mandalay Bay Hotel in Las Vegas from April 23 to April 25.
The following posters and abstracts will be presented at the SAWC:
- Autolytic Debridement and Healing of Neonatal and Pediatric Wounds with Active Leptospermum Honey. Dr. Rene Amaya, MD, Pediatric Infectious Disease Specialists of Houston, Houston, TX
- Use of Active Leptospermum Honey to Aide in Promoting Autolytic Debridement and Wound Healing in Challenging Chronic Wounds. Margarita Simón, APRN, BC, CWCN, Simón Wound Consulting, PLLC / Kim Smith, Executive Director, Gentiva Home Health / Rachele Uptegrow, RN, Gentiva Home Health, Virginia Beach, VA
- Effectiveness of a Leptospermum Honey and a Novel Hydrogel Colloidal Sheet Dressing with Leptospermum Honey with Obstetrical and Gynecological Wounds and Incision Sites. Stefanie A. Schultis, MD, FACOG
- Using Active Leptospermum Honey and Super-absorbent Polymer Dressings to Promote Wound Healing in Chronic Diabetic Foot Ulcers: A Pilot Study. Harikrishna K.R.Nair, MD, FMSWCP, Wound Care Unit, Dept. of Internal Medicine, Kuala Lumpur Hospital, Malaysia
- Use of Active Leptospermum Honey to Manage Wounds of the Oral Cavity. Connie Johnson, RN, BSN, WCC, DAPWCA University Medical Center of Princeton, Plainsboro, NJ
TCC-EZ™ Total Contact Casting System
- Helping to Save Limbs – One Total Contact Cast at a Time. Donna Willemsen, RN, BSN CWS, Cedar Park Regional Wound Care Center, Cedar Park, TX
- TCC – It’s That Easy. Connie Johnson, RN, BSN, WCC, DAPWCA University Medical Center of Princeton, Plainsboro, NJ
- Offloading the Diabetic Foot Ulcer with Total Contact Casting: With an Average Healing Time of 22 Days We Can’t Afford Not To. James Deacon, MD, FCFP, FAPWCA, FAPWH – Quarry Foot Clinic, Kingston, ON
General Wound Healing
- Complications and Skin Failures Related to Malnutrition in the Bariatric Patient. Connie Johnson, RN, BSN, WCC, DAPWCA University Medical Center of Princeton, Plainsboro, NJ
- Holistic Approach: Advanced Wound Product Selection for the Management of Patients with Complex Challenging Wounds. Dimitrios Lintzeris, DO, CWS; Kari Yarrow, RN; Laura Johnson, RN; Amber White, RN; Amanda Hampton, RN; Kristy Albert, PTA; Arlene Cook, PTA; Anthony Strickland, RN, Wayne Memorial Wound Care Center, Goldsboro, NC
Derma Sciences is supporting two educational programs at the SAWC. One, through an unrestricted educational grant to the North American Center for Continuing Medical Education (NACCME), a multi-disciplinary, interactive educational symposium will present Consensus-Driven, Evidence-Based Guidelines for Offloading DFUs: Addressing the Gap in Clinical Practice and Looking at the Latest Data.
In addition, David G. Armstrong, DPM, MD, PhD, Director, Southern Arizona Limb Salvage Alliance (SALSA) Professor of Surgery will moderate a discussion with Kara S. Couch, MS, CRNP, CWS; Nurse Practitioner Complex Wound and Limb Salvage Center, Department of General Surgery at Walter Reed National Military Medical Center and Rene Amaya, MD, FAAP, CMET; Pediatric Specialists of Houston – Infectious Disease and Wound Care entitled, “What is the real story on wound healing and MEDIHONEY®?”
“Derma Sciences is poised to become one of the strongest competitors in the emerging regenerative medicine segment of advanced wound care, and with the significant presence we have at the SAWC there is no better place to launch our new corporate branding campaign,” stated Barry Wolfenson, Group President, Advanced Wound Care and Pharmaceutical Development. “The posters being presented this week are further validation of the burgeoning clinical body of evidence in support of our products’ importance to advanced wound care clinicians and patients. Our new AMNIOEXCEL® products hold additional potential as skin substitutes and we are looking forward to highlighting them at our booth,” Mr. Wolfenson added.
“The primary goal in wound care treatment is always the preservation of function and to maintain the patient’s quality of life. Derma Sciences helps clinicians to deliver advanced treatment options,” commented Michael Kerzner, M.D. of the Wound Management Institute at Duke University Medical Center.
The Symposium on Advanced Wound Care and Wound Healing Society (SAWC Spring/WHS) meeting is the premier interdisciplinary wound care program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists and researchers are expected to attend the 2014 SAWC Spring/WHS meeting.
About Derma Sciences, Inc.
Derma Sciences is a tissue regeneration company focused on advanced wound and burn care. It offers a line of products with patented technologies to help better manage chronic and hard-to-heal wounds, many of which result from diabetes and poor vascular functioning. The company recently entered the $500 million market for skin substitute products with its licensing of AMNIOEXCEL® and AMNIOMATRIX® in the first quarter of 2014. AMNIOEXCEL was launched to customers in March 2014 and AMNIOMATRIX will be launched in the second quarter. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants. Its pharmaceutical wound care products include DSC127, which is currently in Phase 3 clinical trials for the healing of diabetic foot ulcers. The drug candidate is also part of a BARDA grant program for the healing/prevention of tissue damage due to ionizing radiation exposure. The patented API peptide used in DSC127 is also in preclinical testing for scar prevention/reduction. The company also offers a full product line of traditional dressings.
For more information please visit www.dermasciences.com.
Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the company. Factors that may affect the company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the company's actual results and forward-looking statements include but are not limited to, those discussed in the company's filings with the U.S. Securities and Exchange Commission.